bromodeoxyuridine has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Czerwonka, A; Luszczki, J; Okon, E; Telejko, I; Wawruszak, A | 1 |
| Du, Y; Kong, Y; Lu, X; Ma, J; Sun, J; Xie, H; Xu, S; Yan, T; Yu, L; Zhou, L | 1 |
2 other study(ies) available for bromodeoxyuridine and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Additive pharmacological interaction between sirtuin inhibitor cambinol and paclitaxel in MCF7 luminal and MDA-MB-231 triple-negative breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Bromodeoxyuridine; Cell Line, Tumor; Cell Proliferation; Female; Histone Deacetylase Inhibitors; Humans; Paclitaxel; Sirtuins; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2022 |
GLDC mitigated by miR-30e regulates cell proliferation and tumor immune infiltration in TNBC.
Topics: Bromodeoxyuridine; Cell Line, Tumor; Cell Proliferation; Estrogens; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Receptors, Progesterone; RNA, Messenger; Triple Negative Breast Neoplasms | 2022 |